Abstract
Introduction Hu antibodies have previously been associated with longer survival of patients with small-cell lung cancer (SCLC). VGCC antibodies play a pathogenic role in the Lambert Eaton myasthenic syndrome (LEMS) which is also associated with SCLC, and these antibodies may reduce tumour growth. We tested a large cohort of sera from SCLC patients to see whether Hu and VGCC antibodies correlated with better SCLC prognosis. Method 200 patients with SCLC (age 39–79, mean 62.3 years; 129 males and 71 females) receiving similar treatment were studied. Sera from these patients were examined for Hu antibodies by an immunoprecipitation assay and by imunohistochePosters, Monday, October 28 133
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
